[其他期刊] Safety, Biodistribution, and Dosimetry of FAP and Integrin αvβ3Dual-Targeting Radioligand177Lu-DOTA-FAPI-RGD: Preclinical Validation and First-in-Human Study in Patients with Advanced Adenocarcinomas |
50
20
20
20
20